ArticleArthritis research & therapy2022

Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis.

Masahiro Kondo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.